Core Viewpoint - Kamada reported strong operational and financial performance in 2025, with positive momentum heading into 2026, despite potential logistical challenges due to the situation in the Middle East [1]. Operations Update and 2025 Results - The manufacturing plant has been operating continuously, with operations and product manufacturing proceeding as planned. Although exports from Israel may face temporary impacts due to airspace closures, cargo flights have resumed, and no material disruption to product supply is anticipated [2]. - For the full year 2025, total revenues reached $180.5 million, reflecting a 12% year-over-year increase, while adjusted EBITDA was $42 million, up 23%. The company generated $25.5 million in cash from operating activities, resulting in a year-end cash position of $75.5 million [2]. Revenue Growth Drivers - Revenue growth in 2025 was attributed to increased sales across the portfolio, particularly for Varizig and KedRAB in the U.S., KAMRAB and GLASSIA in international markets, and higher distribution segment sales supported by biosimilar launches and other products [3]. Dividend Declaration and 2026 Outlook - Based on the strong 2025 results, the board declared a dividend of $0.25 per share, totaling approximately $14.4 million, payable on April 6 to shareholders of record as of March 23. This aligns with the company's policy to distribute at least 50% of annual net income as dividends [4]. - The company affirmed its 2026 guidance, projecting revenues of $200 million to $205 million and adjusted EBITDA of $50 million to $53 million, representing growth of 13% and 23% respectively compared to 2025 results. The outlook is based solely on organic growth, with any business development or M&A activities considered incremental [5]. Product and Commercial Highlights - KedRAB, the company's lead product, saw sales to Kedrion Biopharma increase to approximately $54 million in 2025, exceeding the contract minimum commitment. Kamada has a firm commitment of $90 million from Kedrion for minimum orders from 2026 through 2027, with the current supply agreement extending through 2031 [6].

Financial Data and Key Metrics Changes - Total revenues for 2025 were $180.5 million, representing a 12% year-over-year increase from $161 million in 2024 [5][17] - Adjusted EBITDA was $42 million, up 23% year-over-year from $34.1 million in 2024 [5][19] - Net income for 2025 was $20.2 million or $0.35 per diluted share, a 40% increase compared to $14.5 million or $0.25 per diluted share in 2024 [19] - Cash and cash equivalents at year-end 2025 were $75.5 million, down from $78.4 million in December 2024 [19] Business Line Data and Key Metrics Changes - Sales of KedRAB increased to approximately $54 million in 2025, exceeding the contract minimum commitment [10] - GLASSIA contributed total revenue of $35 million, with growth in both ex-U.S. markets and royalty income from Takeda [10] - Revenues from Cytogam declined due to increased usage of antivirals, with ongoing efforts to demonstrate its advantages through a new clinical study [11][12] Market Data and Key Metrics Changes - The company secured a $10 million-$14 million extension of an existing tender from Canadian Blood Services for various products, ensuring ongoing sales in Canada from Q2 2026 to Q1 2028 [17] - The distribution segment is expected to grow through the launch of additional biosimilars in Israel and expansion into the MENA region [9][14] Company Strategy and Development Direction - The company focuses on expanding its commercial product portfolio, including investment in FDA-approved specialty plasma-derived products and biosimilars [9] - Plans to ramp up plasma collection at new centers in Houston and San Antonio, with expected annual revenues of $8 million-$10 million at full capacity [15] - The company aims to secure new business development and M&A transactions to enhance its product portfolio and generate synergies [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to meet supply obligations despite geopolitical challenges in the Middle East [4] - The company affirmed its 2026 annual guidance of $200 million-$205 million in revenues and $50 million-$53 million in adjusted EBITDA, representing 13% and 23% growth, respectively [8] - Management emphasized the importance of Cytogam as additional protection for high-risk organ transplant recipients and the potential for increased usage following clinical studies [25] Other Important Information - A dividend of $0.25 per share, totaling approximately $14.4 million, was declared, reinforcing confidence in business prospects and liquidity for growth investments [6][7] Q&A Session Summary Question: CMV market and Cytogam usage - Management noted no changes in CMV management protocols but acknowledged increased access to antivirals affecting Cytogam usage [23][24] Question: M&A opportunities and dividend implications - Management confirmed that the dividend payment does not indicate a change in M&A opportunities, expressing optimism for securing transactions in 2026 [26] Question: Plasma collection growth margin benefits - Management expects growth margin benefits from proprietary plasma collection to start impacting gross profit in 2027 and beyond [27] Question: Plasma collection center ramp-up - Current ramp-up is at 30%-40%, with full capacity expected by the end of 2027 [31] Question: Timing for new biosimilars - New biosimilars are expected to launch around mid-2026, with sales ramping up based on market demand [32] Question: Dividend payment timing - The entire dividend will be paid out in the second quarter [40]

Financial Data and Key Metrics Changes - Total revenues for 2025 were $180.5 million, representing a 12% year-over-year increase from $161 million in 2024 [5][17] - Adjusted EBITDA was $42 million, up 23% year-over-year from $34.1 million in 2024 [5][19] - Net income for 2025 was $20.2 million or $0.35 per diluted share, a 40% increase compared to $14.5 million or $0.25 per diluted share in 2024 [19] - Cash and cash equivalents at year-end 2025 were $75.5 million, down from $78.4 million in December 2024 [19] Business Line Data and Key Metrics Changes - Sales of KedRAB increased to approximately $54 million in 2025, exceeding the contract minimum commitment [10] - GLASSIA contributed total revenue of $35 million, with growth in both ex-U.S. markets and royalty income from Takeda [10] - Revenues from Cytogam declined due to increased usage of antivirals, with ongoing efforts to demonstrate its advantages through a new clinical study [11][12] Market Data and Key Metrics Changes - The company secured a $10 million-$14 million extension of an existing tender from Canadian Blood Services for various products, ensuring ongoing sales in Canada from Q2 2026 to Q1 2028 [17] - The company anticipates growth in its distribution segment through the launch of additional biosimilars in Israeli markets and expansion into the MENA region [9][14] Company Strategy and Development Direction - The company focuses on expanding its commercial product portfolio, including investment in FDA-approved specialty plasma-derived products and biosimilars [9] - Plans to ramp up plasma collection at new centers in Houston and San Antonio, with expected annual revenues of $8 million-$10 million per center at full capacity [15] - The company is pursuing new business development and M&A opportunities to enhance its product portfolio and generate synergies [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's operational and financial performance, despite geopolitical challenges in the Middle East [4] - The company affirmed its 2026 annual guidance of $200 million-$205 million in revenues and $50 million-$53 million in adjusted EBITDA, representing growth from 2025 results [8] - Management emphasized the importance of Cytogam in organ transplant protection and the potential for increased usage following clinical studies [25] Other Important Information - A dividend of $0.25 per share was declared, totaling approximately $14.4 million, reinforcing confidence in business prospects [6][7] - The company plans to continue investing in growth while maintaining dividend payments [26] Q&A Session Summary Question: CMV market and Cytogam usage - Management noted no changes in CMV management protocols but acknowledged increased access to antivirals affecting Cytogam usage [23][24] Question: M&A opportunities and dividend implications - Management confirmed that the dividend payment does not indicate a change in M&A opportunities, expressing optimism for securing transactions in 2026 [26] Question: Plasma collection growth margin benefits - Management expects growth margin benefits from plasma collection to start impacting gross profit in 2027 and beyond [27] Question: Plasma collection center ramp-up - Current ramp-up is at 30%-40%, with full capacity expected by the end of 2027 [31] Question: Timing for new biosimilars launch - New biosimilars are expected to launch around mid-2026, with sales ramping up based on market demand [32] Question: Dividend payment timing - The entire dividend will be paid in the second quarter [39]

Financial Data and Key Metrics Changes - Total revenues for 2025 were $180.5 million, a 12% year-over-year increase from $161 million in 2024 [5][17] - Adjusted EBITDA for 2025 was $42 million, reflecting a 23% increase compared to $34.1 million in 2024 [5][19] - Net income for 2025 was $20.2 million, or $0.35 per diluted share, a 40% increase from $14.5 million, or $0.25 per diluted share, in 2024 [19] - Cash and cash equivalents at year-end 2025 were $75.5 million, down from $78.4 million in December 2024 [19] Business Line Data and Key Metrics Changes - Sales of KedRAB increased to approximately $54 million in 2025, exceeding the contract minimum commitment [10] - GLASSIA contributed total revenue of $35 million, with growth in ex-U.S. markets and royalty income from Takeda [10] - Revenue from Cytogam declined due to increased usage of antivirals, but a comprehensive post-marketing research program is expected to support future growth [11][12] Market Data and Key Metrics Changes - The company anticipates growth in the distribution segment through the launch of additional biosimilars in Israeli markets and expansion into the MENA region [9][13] - The Canadian Blood Services awarded a $10 million-$14 million extension for the supply of various products, securing ongoing sales in the Canadian market [17] Company Strategy and Development Direction - The company focuses on expanding its commercial product portfolio and investing in the commercialization of FDA-approved specialty plasma-derived products [9] - Plans to ramp up plasma collection at new centers, aiming for significant revenue generation from normal source plasma sales starting in 2026 [14] - The company is pursuing M&A opportunities to enrich its product portfolio and generate synergies with existing operations [15][16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's operational and financial performance, despite geopolitical challenges in the Middle East [4] - The company affirmed its 2026 guidance of $200 million-$205 million in revenues and $50 million-$53 million in adjusted EBITDA, representing growth from 2025 results [7][8] - Management emphasized the importance of Cytogam in organ transplant protection and the potential for increased utilization following ongoing clinical studies [24] Other Important Information - A dividend of $0.25 per share, totaling approximately $14.4 million, was declared, reinforcing confidence in business prospects and liquidity [6] - The company expects to launch two additional biosimilars in Israel in mid-2026, contributing to growth in the distribution business [13][32] Q&A Session Summary Question: Impact of antivirals on Cytogam market - Management noted no change in CMV management protocols but acknowledged increased access to antivirals affecting Cytogam usage [22][23] Question: M&A opportunities and dividend implications - Management confirmed that the dividend payment does not indicate a change in M&A opportunities, expressing optimism for securing transactions in 2026 [25] Question: Plasma collection growth margin benefits - Management expects growth margin benefits from proprietary plasma collection to start impacting gross profit in 2027 and beyond [26] Question: Ramp-up of plasma collection centers - Current ramp-up is at 30%-40%, with full capacity expected by the end of 2027 [31] Question: Timing of biosimilars launch - Two additional biosimilars are expected to launch around mid-2026, with sales ramping up based on market demand [32] Question: Dividend payment schedule - The entire dividend will be paid in the second quarter [40]

Kamada (KMDA) FY Conference Summary Company Overview - Kamada is a publicly traded biopharmaceutical company with a commercial stage and six FDA approved products [2][3] - The company has experienced significant growth, with a revenue guidance of $178 million to $182 million for the year, and an EBITDA guidance of $40 million to $44 million [3][10] Financial Performance - Revenue has shown double-digit growth since 2021, starting from approximately $100 million to a projected $180 million this year [10] - EBITDA has increased from $6 million to over $40 million, with a growth rate from 6%-7% to around 24%-25% [10] - The company reported an 11% growth in revenue, 58% growth in earnings per share, and 35% growth in adjusted EBITDA compared to the previous year [11] Growth Strategy - Kamada's growth strategy is based on four pillars: organic growth, M&A, in-licensing of additional products, and opening plasma collection centers [4][12] - The company has opened two plasma collection centers in Houston and San Antonio, with a capacity of around 50,000 donations annually, expected to generate $8 million to $10 million in additional revenue [14][15] - The company is optimistic about potential M&A opportunities that could positively impact profitability by 2026 [13] Product Portfolio - Kamada focuses on specialty plasma-derived products, including alpha-one antitrypsin and five specialty immunoglobulins [5][6] - Key products include: - **Kedra**: An anti-rabies immunoglobulin product, with a market share of approximately 50% and a partnership with Kedrion [16][18] - **CytoGam**: An anti-CMV immunoglobulin used in organ transplantation, with ongoing data collection to support its use [19][39] Market Dynamics - The market for alpha-one deficiency is estimated at $1.3 billion to $1.4 billion, with potential growth to $1.8 billion to $2 billion by 2029 [29][31] - The company is developing a nebulized AAT product to improve treatment efficiency, with a Phase III pivotal study currently underway [27][28] Competitive Landscape - Kamada has carved out a niche in the specialty plasma space, as larger companies have exited due to the market size being too small for them [44][45] - The company does not foresee new plasma companies entering the market due to high entry barriers and complex supply chains [49] - Competition exists from non-plasma products, such as recombinant AAT and gene therapy treatments [50] Future Outlook - Kamada plans to continue expanding its product offerings and market presence, with a focus on partnerships for commercial capabilities in the alpha-one space [41][42] - The company aims to maintain its position as a leading global specialty plasma company, leveraging its unique expertise and capabilities [51]

Financial Data and Key Metrics Changes - Total revenues for the first half of 2025 were $88.8 million, representing an 11% year-over-year increase, while adjusted EBITDA was $22.5 million, up 35% year-over-year, with a 25% margin on revenues [4][11] - For the second quarter, revenues were $44.8 million, up 5% compared to the prior year quarter, and adjusted EBITDA was $10.9 million, up 20% year-over-year [4][11] - Net income for the first half of 2025 was $11.3 million or $0.19 per diluted share, compared to $6.8 million or $0.12 per diluted share in 2024 [13][14] Business Line Data and Key Metrics Changes - Revenue growth for the first half of 2025 was primarily driven by increased sales of Glacier in ex-U.S. markets and VariSig sales in the U.S., as well as Glacier royalty payments [6][7] - The company anticipates launching two additional biosimilars later this year, with expected revenues of approximately $2.5 million in 2025 from the first biosimilar launched in Israel [7][8] Market Data and Key Metrics Changes - The company is ramping up plasma collection at its Texas-based plasma centers, with each center expected to generate annual revenues of between $8 million to $10 million at full capacity [9] - The market for inhaled alpha-one antitrypsin therapy is projected to grow significantly, with expectations that it could reach a $2 billion market by the time the company has results from its study [26] Company Strategy and Development Direction - The company is guided by a four-pillar growth strategy focusing on organic commercial growth, business development and M&A transactions, plasma collection operations, and the advancement of its pivotal Phase III Inhaled AAT program [5][41] - The company is actively conducting due diligence on several potential commercial targets to enrich its portfolio and expects to secure compelling in-licensing collaborations or M&A transactions [8][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in continuing to generate profitable growth through the remainder of 2025 and has increased its adjusted EBITDA guidance to between $40 million to $44 million [5][14] - The company is closely monitoring the evolving tariff situation, assessing that recently imposed tariffs are not applicable to drug products and have not impacted operations [15] Other Important Information - The company ended the first half of 2025 with a cash balance of $66 million, which is planned to be used for new business development initiatives [14] - Gross profit for the first half of 2025 was $39.7 million with a gross margin of 45%, compared to $35.7 million and 45% in 2024 [12] Q&A Session Summary Question: Dynamics behind KEDRAB and Cytogam - Management indicated that KEDRAB and Cytogam are performing according to expectations, with growth anticipated once additional clinical data is available [17][19] Question: Cash position for impactful business development - Management plans to utilize existing cash and has additional funding sources available for commercial stage assets, focusing on plasma-derived products and specialty pharma [22][23] Question: Competitive landscape for inhaled AAT program - Management noted that their inhaled AAT program is the most advanced in terms of efficacy studies, with a growing market and multiple new technologies being developed [24][26] Question: Distribution revenue segment and future outlook - Management confirmed that the revenue from the new biosimilar product is not a one-time sale and expects continued growth in the distribution channel [30][31] Question: SG&A expenses and future expectations - Management stated that they have been disciplined in managing expenses and anticipate a slight fluctuation in the second half of the year but aim to maintain profitability [33][34] Question: Tax rate expectations - Management expects an effective tax rate between 20% and 25% as the company utilizes its tax loss carryforwards [35][38]